Goldman Sachs
VOR icon

Goldman Sachs’s Vor Biopharma VOR Stock Holding History

Goldman Sachs’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.05M Buy
328,892
+67,001
+26% +$1.01M ﹤0.01% 3709
2026
Q1 		$4.67M Buy
261,891
+116,251
+80% +$1.64M ﹤0.01% 3773
2025
Q4 		$1.9M Buy
145,640
+129,854
+823% +$2.42M ﹤0.01% 4636
2025
Q3 		$769K Buy
15,786
+6,747
+75% +$271K ﹤0.01% 5224
2025
Q2 		$293K Buy
9,039
+4,792
+113% +$42.3K ﹤0.01% 5453
2025
Q1 		$60.9K Buy
4,247
+2,912
+218% +$69.9K ﹤0.01% 5863
2024
Q4 		$29.6K Sell
1,335
-76
-5% -$1.26K ﹤0.01% 5873
2024
Q3 		$19.8K Sell
1,411
-17,356
-92% -$316K ﹤0.01% 5674
2024
Q2 		$375K Buy
18,767
+14,108
+303% +$456K ﹤0.01% 4983
2024
Q1 		$221K Buy
4,659
+2,742
+143% +$120K ﹤0.01% 5083
2023
Q4 		$86.3K Buy
1,917
+639
+50% +$26.4K ﹤0.01% 5317
2023
Q3 		$54.2K Sell
1,278
-811
-39% -$44K ﹤0.01% 5270
2023
Q2 		$129K Sell
2,089
-2,575
-55% -$235K ﹤0.01% 5311
2023
Q1 		$502K Buy
+4,664
New +$517K ﹤0.01% 4822
2022
Q4 		– Sell
-953
Closed -$76K – 6287
2022
Q3 		$76K Sell
953
-424
-31% -$41.7K ﹤0.01% 5741
2022
Q2 		$137K Buy
1,377
+97
+8% +$9.9K ﹤0.01% 5763
2022
Q1 		$155K Buy
1,280
+418
+48% +$71.2K ﹤0.01% 5967
2021
Q4 		$200K Buy
+862
New +$249K ﹤0.01% 5903

Other funds holding VOR

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCPM III Services
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Goldman Sachs's VOR Position: Q2 2026 in Review

Goldman Sachs increased its Vor Biopharma (VOR) stake by 26% in Q2 2026, buying an estimated $1.01M and bringing the position to 328,892 shares worth $6.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

Goldman Sachs first reported a position in VOR in Q4 2021 and has held it in 18 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Goldman Sachs held 328,892 shares of Vor Biopharma worth $6.05M as of Q2 2026.
  • Goldman Sachs bought 67,001 Vor Biopharma shares in Q2 2026, an estimated $1.01M.
  • Vor Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3709 holding.
  • Goldman Sachs first reported a position in Vor Biopharma in Q4 2021 and has held it in 18 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.